Journal of Pharmacological Sciences · 2015 · 15 citations · 12 references
MedicineMedicinal ChemistryPharmacologyClinical PharmacologyDrug DiscoveryMolecular PharmacologyEnzyme InhibitionReceptor PharmacologySodium-glucose Cotransporter 2 InhibitorsTransporter PharmacologyDissociation EquilibriumGlucose TransportGlucose Transporter 2In-vitro CharacterizationInhibition KineticsInhibition ModelSodium-glucose CotransportSodium-glucose Cotransporter 2 Inhibition
In this study, we evaluated an inhibition model of luseogliflozin on sodium glucose co-transporter 2 (SGLT2). We also analyzed the binding kinetics of the drug to SGLT2 protein using [(3)H]-luseogliflozin. Luseogliflozin competitively inhibited human SGLT2 (hSGLT2)-mediated glucose uptake with a Ki value of 1.10 nM. In the absence of glucose, [(3)H]-luseogliflozin exhibited a high affinity for hSGLT2 with a Kd value of 1.3 nM. The dissociation half-time was 7 h, suggesting that luseogliflozin dissociates rather slowly from hSGLT2. These profiles of luseogliflozin might contribute to the long duration of action of this drug.
12
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
James F. List, Vincent Woo, Enrique Morales et al. · Diabetes Care · 2008 · 696 citations · Full text
Masayuki Suzuki, Kiyofumi Honda, Masanori Fukazawa et al. · Journal of Pharmacology and Experimental Therapeutics · 2012 · 166 citations
Hiroyuki Kakinuma, Takahiro Oi, Yuko Hashimoto-Tsuchiya et al. · Journal of Medicinal Chemistry · 2010 · 158 citations · Full text